Investigational drug · Phase 3
JAB-3312
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "JAB-3312"
First trial start
2022
Apr 14, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JAB-3312", any sponsor or status.
Conditions studied
As listed on its trial records.
- KRAS P.G12C
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Ductal Carcinoma
- Advanced Non-squamous Non-small-cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "JAB-3312" as an intervention, largest first.
- JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationPivotal-lookingRecruiting
Allist Pharmaceuticals, Inc.Industry
NCT06416410 · 392 participants (planned) · Start Aug 7, 2024 · Primary completion Sep 30, 2029
Drug: JAB-21822; Tislelizumab and 3 more · For: Advanced Non-squamous Non-small-cell Lung Cancer; Metastatic Non-squamous Non Small Cell Lung Cancer
Sites: Hefei, China; Beijing, China; Fuzhou, China · 37 sites in all
Allist Pharmaceuticals, Inc.Industry
NCT05288205 · 240 participants (planned) · Start Apr 14, 2022 · Primary completion Mar 2027
Drug: JAB-21822; JAB-3312 · For: KRAS P.G12C; Non-small Cell Lung Cancer; Colorectal Cancer and 1 more
Sites: Hefei, China; Beijing, China; Fuzhou, China · 27 sites in all
Allist Pharmaceuticals, Inc.Industry
NCT04720976 · 58 participants · Start Mar 23, 2021 · Primary completion Dec 19, 2023
Drug: JAB-3312; Binimetinib and 3 more · For: Solid Tumor; NSCLC
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 15 sites in all
Jacobio Pharmaceuticals Co., Ltd.Industry
NCT04045496 · 40 participants · Start Sep 26, 2019 · Primary completion Dec 16, 2022
Drug: JAB-3312 · For: Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Carcinoma and 4 more
Sites: Denver, Colorado; Nashville, Tennessee; Houston, Texas · 4 sites in all
Allist Pharmaceuticals, Inc.Industry
NCT04121286 · 17 participants · Start Jul 14, 2020 · Primary completion Jun 17, 2022
Drug: JAB-3312 · For: Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Carcinoma and 4 more
Sites: Beijing, China; Henan, China · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.
Zhong J, Zhao J, Duan J, et al. · Lancet Respir Med 2026
- Targeting SHP2 to reverse immune evasion and resistance to anti-PD-1 therapy in non-small cell lung cancer.
Chen S, Wang D, Xiong D, et al. · Cell Commun Signal 2025
- JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies.
Kang D, Wang Y, Lin Y, et al. · Clin Cancer Res 2025
- Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312.
Wang P, Sun X, He X, et al. · Cancer Res Commun 2025
- Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment.
Ma C, Kang D, Gao P, et al. · J Med Chem 2024
Also in development for KRAS P.G12C
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.